Author/Authors :
Dash، Amitabh نويسنده Departments of Pharmacology, Banaras Hindu University, Varanasi?5, Uttar Pradesh , , Maiti، Rituparna نويسنده Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha , , Bandakkanavar، Tejaswi Kumar Akantappa نويسنده Departments of Pharmacology, Banaras Hindu University, Varanasi-5, Uttar Pradesh , , Bhaskar، Amit نويسنده General Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi?5, Uttar Pradesh , , Prakash، Jai نويسنده , , Pandey، Bajarang Lal نويسنده Departments of Pharmacology, Banaras Hindu University, Varanasi-5, Uttar Pradesh ,
Abstract :
Background: Chronic kidney disease (CKD) coexisting with type 2
diabetes mellitus (DM) leads to coronary artery disease. The present
study compares clopidogrel and low?dose aspirin as prophylactic
therapy against coronary events in patients with CKD with diabetes.
Methods: Total 80 patients of CKD with type 2 DM were randomized
and allocated to clopidogrel and aspirin groups to receive the drug
at a dose of 75 mg and 150 mg once daily respectively for 8 weeks
as add-on therapy. Main outcome was change in blood pressure,
metabolic parameters, renal function, inflammatory biomarkers,
platelet aggregability and (UKPDS) United Kingdom Prospective
Diabetes Study risk scoring.
Results: Significant decrease in blood pressure (P < 0.01), total
cholesterol (P = 0.02), LDL (P < 0.01), triglyceride (P < 0.01) and a
better glycemic control (P < 0.01) was found in clopidogrel group.
Renal markers and electrolytes have been improved in clopidogrel
group but in aspirin group there was deterioration (2.5%) of
creatinine clearance. Clopidogrel group has shown a significant
decrease in hsCRP (P < 0.01), UKPDS risk scoring (P < 0.01) and
better anti?aggregatory effect.
Conclusions: Clopidogrel has prophylactic role in CKD with
type 2 DM due to better control of metabolic parameters, renal
function and inflammatory burden in comparison to aspirin.
